文献速递神经免疫

奥瑞珠单抗治疗多发性硬化患者年度MRI监测的价值:需扫描数分析

Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.
PubMed 文献 · Neurology · 2026-07-29

该研究基于阿姆斯特丹MS队列中342例奥瑞珠单抗治疗的多发性硬化患者,分析常规年度MRI随访中放射学疾病活动的发生频率,并计算需扫描数(NNS)。结果显示放射学活动仅见于1.8%的扫描和6.7%的患者,NNS随治疗时间延长而升高,提示稳定患者可安全延长MRI间隔。

要点

  • 奥瑞珠单抗治疗中放射学疾病活动率低,仅1.8%扫描和6.7%患者出现。
  • NNS随治疗时间增加,30个月达81.3,36个月达152.9。
  • 无症状患者常规年度MRI监测从未导致治疗改变,可考虑延长间隔。

核心结论

  • 奥瑞珠单抗治疗的无症状MS患者常规年度MRI监测未导致治疗改变,NNS随时间增加提示可安全延长MRI间隔。

研究设计与样本

  • 研究纳入阿姆斯特丹MS队列中奥瑞珠单抗治疗至少3个月且至少完成2次脑MRI的342例患者,平均年龄40.3岁(SD 10.8),65.8%为女性,208例复发起病MS和41例原发进展型MS,共贡献1639次随访MRI。

主要发现

  • 中位治疗49个月期间,23例患者(6.7%)的29次扫描(1.8%)检测到放射学疾病活动。
  • NNS随治疗时间延长而增加,尤其在治疗24个月后,30个月时达81.3,36个月时达152.9。

关键数值与推荐

  • 放射学活动定义为奥瑞珠单抗起始至少3个月后的MRI扫描出现≥1个对比增强病灶,或后续MRI与起始至少3个月后的扫描相比出现任何新发/增大的T2病灶。

临床怎么用

  • 对于奥瑞珠单抗治疗的无症状稳定MS患者,可考虑从治疗第2年起延长MRI监测间隔,如改为第1年、第2年、第4年、第8年等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Current guidelines recommend annual MRI scans during treatment with disease-modifying therapies, including ocrelizumab, in patients with multiple sclerosis (MS) to monitor treatment effectiveness and safety. However, the low rate of radiologic disease activity during long-term ocrelizumab treatment suggests that this recommendation should be re-evaluated to reduce burden on ocrelizumab-treated patients and the healthcare system. We aimed to describe the frequency of radiologic follow-up and the occurrence of radiologic disease activity in a cohort of ocrelizumab-treated MS patients to provide insight into the clinical value and efficiency of annual MRI monitoring in routine practice. METHODS: We included ocrelizumab-treated MS patients from the Amsterdam MS Cohort, who had at least 2 brain MRI scans performed during ≥3 months of treatment. MRI scans were performed as part of routine clinical care and clinical MRI reports issued by radiologist were used. Radiologic activity was defined as either ≥1 contrast-enhancing lesions on a MRI scan performed ≥3 months after ocrelizumab initiation or any new/enlarging T2 lesions on a subsequent MRI scan compared with a scan performed at least ≥3 months after ocrelizumab initiation. The number needed to scan (NNS) was calculated as the inverse of the predicted probability of radiologic disease activity as a function of treatment duration in months, estimated using a mixed-effects logistic regression model. RESULTS: A total of 342 patients (mean age at start ocrelizumab 40.3 years (SD 10.8); 65.8% female; 208 relapsing-onset MS and 41 primary progressive MS) were included, contributing 1,639 follow-up MRI scans. Radiologic disease activity was detected in 29 scans in 23 patients (1.8% of scans; 6.7% of patients) over a median treatment duration of 49 months. The NNS increased with treatment duration, especially after 24 months of treatment, reaching 81.3 at month 30 and 152.9 at month 36. DISCUSSION: Routine annual MRI monitoring in patients with asymptomatic ocrelizumab-treated MS never led to treatments changes. The increasing NNS over time, especially after 2 years of treatment, indicates that MRI intervals can be safely extended in patients with stable MS treated with ocrelizumab, potentially doubling the interval from treatment year 2 onward (i.e.,; rebaseline, year 1, year 2, year 4, and year 8, etc.).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schoof L, Heijnen R, Hogenboom L, et al. Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis. Neurology. 2026. PMID: 42525900. doi:10.1212/WNL.0000000000218379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。